Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome (CNSY) reported Q3 2026 gross billings of $1.55M for CNSide Diagnostics. The company expects to cover 200M lives by early 2027 and launch new tests in Q4 2026. Annualized billing run rate is projected to reach $10M-$12M by Q4 2026, according to management.
How this was made
The 30-second read
Why it matters
The disclosed gross billings and Medicare pricing decision provide the first concrete financial guidance for the quarter, offering a new data point for valuation.
Market read
First‑time disclosure of Q3 billing figures and future run‑rate expectations; modest relevance for traders tracking micro‑cap biotech news.
What to watch
Potential reimbursement delays or competition from larger diagnostics firms could limit upside.
Background
Cerenome (Nasdaq:CNSY) provides a business update for its CNSide Diagnostics subsidiary, outlining test volume, coverage, and billing projections.
Ticker impact
Cerenome disclosed Q3 2026 gross billings of $1.55M and projected annualized billing run‑rate of $10‑12M, plus coverage expansion to ~200M lives.
potential modest upside as investors price in higher future billings
Guidance is modest in absolute terms for a micro‑cap; market may react positively but impact likely limited.
Market effects
May signal growing demand for CNS oncology diagnostics, modestly supporting the broader health‑tech sector.
Primarily U.S. biotech investors; limited broader regional effect.
Low; the update is company‑specific without macro implications.
Counterpoint
The guidance may be overly optimistic given the early stage of test adoption; price could stay flat.
Key entities
- companyCerenome, Inc.
US‑listed biotech focused on CNS oncology diagnostics.
- subsidiaryCNSide Diagnostics, LLC
Wholly owned unit developing CNSide® tests.
